JP-1366 10 mg

DRUG2 trials

Sponsors

Onconic Therapeutics Inc.

Conditions

Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)Peptic Ulcer

Phase 3

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

RecruitingNCT06439563

Onconic Therapeutics Inc.Peptic Ulcer

Start: 2024-10-22End: 2027-12-31Target: 364Updated: 2024-11-01

Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis

Not yet recruitingNCT07732075

Onconic Therapeutics Inc.Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)

Start: 2026-08-01End: 2028-10-30Target: 384Updated: 2026-07-28